Innovative delivery of insulin via the lung

Diabetes, Obesity and Metabolism, Supplement

Volumn 7, Issue 1, 2005, Pages

  Patton, John S ^a  

^a NEKTAR THERAPEUTICS   (United States)

Author keywords

Diabetes; Exubera ; Inhaled insulin; Pulmonary delivery

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; INSULIN LISPRO;

AEROSOL; CLINICAL TRIAL; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRY POWDER; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; LIVER CLEARANCE; LUNG; MACROMOLECULE; PATIENT COMPLIANCE; PHARMACODYNAMICS; REVIEW;

EID: 27844558794     PISSN: 14657740     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Cefalu WT. Concept, strategies, and feasibility of non-invasive insulin delivery. Diabetes Care 2004; 27: 239-246.
2. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004; 43: 781-801.
3. American Conference of Governmental Industrial Hygienists. 1993-94 Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. OH, Cincinnati, 1993; 29.
4. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev 1999; 35: 235-247.
5. Smith SJ, Bernstein JA. In: Hickey AJ ed. Inhalation Aerosols: Physical and Biological Basis for Therapy. New York, NY: Marcel Dekker, 1996; 233-269.
6. Patton JS. Deep-lung delivery of therapeutic proteins. Chemtech 1997; 27: 34-38.
7. Bryon PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986; 75: 433-438.
8. Schatz H. Inhaled insulin and the dream of a needle-free insulin application. Exp Clin Endocrinol Diabetes 2004; 112: 285-287.
9. Gelfand RA, Schwartz SL, Horton ML, Law CG, Pun EF. Pharmacological reproducibility of inhaled human insulin pre-meal dosing in patients with type 2 diabetes mellitus (Abstract). Diabetes 1998; 47 (Suppl. 1): A99.
10. Gelfand RA, Schwartz SL, Horton M, Law CG, Pun EF. Pharmacological reproducibility of inhaled insulin dosed pre-meal in patients with type 2 DM (Abstract). Diabetologia 2000; 43 (Suppl. 1): A202.
11. Henry R, Mudaliar S, Fryburg D et al. Within-subject variability of inhaled insulin versus subcutaneous regular insulin in elderly obese patients with type 2 diabetes mellitus. Diabetes 2003; 52: 448.
12. Skyler JS, Cefalu WT, Kourides IA et al. Efficacy of inhaled insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357: 331-335.
13. Cefalu WT, Skyler JS, Kourides IA et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001; 134: 203-207.
14. Hollander PA, Blonde L, Rowe R et al. Efficacy and safety of inhaled insulin (Exubera®) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care 2004; 27: 2356-2362.
15. Quattrin T, Bélanger A, Bohannon NJV, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera®) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2622-2627.
16. Rosenstock J, Cappalleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera®) in patients with type 1 or type 2 diabetes. Diabetes Care 2004; 27: 1318-1323.
17. Skyler J for the Exubera® Phase II Study Group. Sustained long-term efficacy and safety of inhaled insulin (Exubera®) during 4 years of continuous therapy. Diabetes 2004; 53 (Suppl. 2): A115.
18. Heinemann L, Hohmann A, Starke AAR et al. What is the correct timing of subcutaneous injections of regular insulin to cover carbohydrate rich meals? Horm Metab Res Suppl 1992; 26: 137-139.
19. Rave K, Bott S, Heinemann L et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005; 28: 1077-1082.
20. Heinemann L, Heise T, Wahl LC et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys (B28), Pro (B29)] human insulin. Diabet Med 1996; 13: 625-629.
21. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys (B28), Pro (B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
22. Del Sindaco P, Ciofetta M, Lalli C et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 1998; 15: 592-600.
23. Ciofetta M, Lalli C, Del Sindaco P et al. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999; 22: 795-800.